metformin has been researched along with Skin Diseases in 10 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Skin Diseases: Diseases involving the DERMIS or EPIDERMIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the pathogenesis of systemic sclerosis is not exactly known, it is thought that immune activation has prominent roles in pathogenesis." | 5.62 | Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. ( Akar, ZA; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2021) |
| "Metformin is an effective and safe adjuvant in the therapeutic scheme of various inflammatory dermatoses, skin neoplasms, endocrinology-related dermatosis, melasma, skin aging and wound healing processes." | 5.22 | [The role of metformin in the treatment of dermatological diseases: A narrative review]. ( Arbués-Espinosa, P; Cruañes-Monferrer, J; García-Gil, MF; Martínez-Cisneros, S; Monte-Serrano, J; Villagrasa-Boli, P, 2022) |
| "Although the pathogenesis of systemic sclerosis is not exactly known, it is thought that immune activation has prominent roles in pathogenesis." | 1.62 | Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis. ( Akar, ZA; Celik, C; Dagli, AF; Etem, EO; Karatas, A; Koca, SS; Oz, B, 2021) |
| "Metformin (MET) has anti-inflammatory and anti-fibrotic effects, but its effect on the in vivo pathogenesis of scleroderma remains unknown." | 1.51 | Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation. ( Feng, M; Gao, C; Guo, H; Li, X; Liang, Z; Luo, J; Qin, K; Wang, Y; Zhang, S; Zhao, X, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Monte-Serrano, J | 1 |
| Villagrasa-Boli, P | 1 |
| Cruañes-Monferrer, J | 1 |
| Arbués-Espinosa, P | 1 |
| Martínez-Cisneros, S | 1 |
| García-Gil, MF | 1 |
| Chen, Q | 1 |
| Zhang, H | 1 |
| Yang, Y | 1 |
| Zhang, S | 2 |
| Wang, J | 1 |
| Zhang, D | 1 |
| Yu, H | 1 |
| Mostafa, DK | 1 |
| Nayel, OA | 1 |
| Abdulmalek, S | 1 |
| Abdelbary, AA | 1 |
| Ismail, CA | 1 |
| Sung, CT | 1 |
| Chao, T | 1 |
| Lee, A | 1 |
| Foulad, DP | 1 |
| Choi, F | 1 |
| Juhasz, M | 1 |
| Dobry, A | 1 |
| Mesinkovska, NA | 1 |
| Chang, JE | 1 |
| Choi, MS | 1 |
| Karatas, A | 1 |
| Celik, C | 1 |
| Oz, B | 1 |
| Akar, ZA | 1 |
| Etem, EO | 1 |
| Dagli, AF | 1 |
| Koca, SS | 1 |
| Wang, Y | 1 |
| Liang, Z | 1 |
| Feng, M | 1 |
| Zhao, X | 1 |
| Qin, K | 1 |
| Gao, C | 1 |
| Li, X | 1 |
| Guo, H | 1 |
| Luo, J | 1 |
| Badr, D | 1 |
| Kurban, M | 1 |
| Abbas, O | 1 |
| Heymann, WR | 1 |
| Harris, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism: A Double-Blind, Randomized, Placebo-Controlled Study[NCT03629639] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Efficacy and Safety of Topical Metformin Emulgel Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: A Split Face Study[NCT05536193] | Phase 4 | 34 participants (Anticipated) | Interventional | 2022-09-10 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for metformin and Skin Diseases
| Article | Year |
|---|---|
[The role of metformin in the treatment of dermatological diseases: A narrative review].
Topics: Dermatitis; Humans; Melanosis; Metformin; Skin Diseases; Spain | 2022 |
Oral Metformin for Treating Dermatological Diseases: A Systematic Review.
Topics: Administration, Oral; Dermatologic Agents; Drug Therapy, Combination; Humans; Metformin; Off-Label U | 2020 |
A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders.
Topics: Acanthosis Nigricans; Acne Vulgaris; Dermatitis, Allergic Contact; Hidradenitis Suppurativa; Humans; | 2020 |
Metformin in dermatology: an overview.
Topics: Humans; Metformin; Skin Diseases | 2013 |
Metformin in dermatology: an overview.
Topics: Humans; Metformin; Skin Diseases | 2013 |
Metformin in dermatology: an overview.
Topics: Humans; Metformin; Skin Diseases | 2013 |
Metformin in dermatology: an overview.
Topics: Humans; Metformin; Skin Diseases | 2013 |
6 other studies available for metformin and Skin Diseases
| Article | Year |
|---|---|
Metformin Attenuates UVA-Induced Skin Photoaging by Suppressing Mitophagy and the PI3K/AKT/mTOR Pathway.
Topics: Animals; Fibroblasts; Metformin; Mice; Mitophagy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Pro | 2022 |
Modulation of autophagy, apoptosis and oxidative stress: a clue for repurposing metformin in photoaging.
Topics: Animals; Antioxidants; Apoptosis; Autophagy; Cathepsin D; Female; Metformin; Mice; Oxidative Stress; | 2022 |
Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17 levels in bleomycin-induced dermal fibrosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Bleomycin; Collagen; Disease Models, Animal; Female; Fib | 2021 |
Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg/Teff cells and reducing spleen germinal center formation.
Topics: Animals; Bleomycin; Cell Differentiation; Collagen; Disease Models, Animal; Female; Fibrosis; Germin | 2019 |
Hyperandrogenism and the skin.
Topics: Acne Vulgaris; Adrenal Hyperplasia, Congenital; Female; Humans; Hyperandrogenism; Male; Metformin; P | 2004 |
Adverse reactions to oral antidiabetic agents.
Topics: Acetohexamide; Acidosis; Administration, Oral; Anemia; Chlorpropamide; Drug Antagonism; Drug Synergi | 1971 |